NRC FORM 374 PAGE OF4_ PAGES							
U.S. NUCLEAR REGULATORY COMMISSION							
Amendment No. 53							
MATERIALS LICENSE							
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.							
Licensee	In accordance with the letter dated March 27, 2008,						
1. W.A. Foote Memorial Hospital	 License number 21-00258-06 is amended in its entirety to read as follows: 						
2. 205 N. East Avenue	4. Expiration date February 28, 2011						
Jackson, MI 49201	5. Docket No. 030-01990 Reference No.						
 Byproduct, source, and/or special nuclear 7. Chemical an material 	nd/or physical form 8. Maximum amount that licensee may possess at any one time under this license						
A. Any byproduct material A. Any permitted by 10 CFR 35.100	A. As needed						
B. Any byproduct material B. Any permitted by 10 CFR 35.200	B. As needed						
C. Any byproduct material C. Any permitted by 10 CFR 35.300	C. 1 Curie						
D. Any byproduct material permitted by 10 CFR 31.11 D. Prepac	kaged Kits D. 1 millicuire						
E. lodine-131 E. Sodium	n-iodide E. 10 millicuries						

NRC	FORM 374A U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 4 PAGES						
		License Number 21-00258-06						
MATERIALS LICENSE		Docket or Reference Number 030-01990						
		Amendment No. 53						
	Byproduct, source, and/or special nuclear 7. Chemical and/or physical form 8. Maximum amount that licensee may material license							
	 F. lodine-125 permitted by 10 CFR 35.400. F. Sealed Sources (Medi-Physics, Inc. or Amersham Health Models 6711 (OncoSeed™), 6733 (EchoSeed™), 6735, Best Medical International, Inc., Model 2301, North American Scientific, Inc., Model MED3631, IsoAid L.L.C. Model IAI- 125A (Advantage™ I- 125), and Bard Brachytherapy, Inc., STM 1251) 							
9.	Authorized use:							
	A. Any uptake, dilution and excretion study permitted by	10 CFR 35.100.						
	B. Any imaging and localization study permitted by 10 CFR 35.200.							
	C. Any diagnostic study or therapy procedure permitted	by 10 CFR 35.300.						
	D. In <u>vitro</u> studies.							
	E. Any iodine-131sodium iodide procedure for imaging and localization studies that requires a written directive in accordance with 10 CFR 35.40.							
	F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.							
	CONDITIONS							
10.	Licensed material may be used or stored only at the licen Jackson, Michigan and Paul Tejada Center, 1102 E. Mich							

NRC	FOR	M 374A U.S. NUCLEAR REGULATORY COM	MISSION	PAGE 3 of 4 PAGES				
			License Number 21-00258-06					
		MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-01990				
				Amendment No. 53				
				<u> </u>				
11.	1. The Radiation Safety Officer for this license is Randall Bardwell.							
12.	Lic	ensed material is only authorized for use by, o	or under	the supervision of:				
	A. Individuals permitted to work as an authorized user,and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.							
	B. The following individuals are authorized users for medical use as indicated:							
		Authorized Users	<u>Materi</u>	al and Use				
		Piyashbhai Chaturbhai Patel, M.D.	10 CFI	R 35.100, 35.200, 35.300, and 31.11.				
		Sadasiva T. Reddy, M.D.	10 CFI	R 35.100, 35.200, 35.300, and 31.11.				
		Libby Anderson, M.D.	10 CFI	R 35.100, 35.200, 35.300, and 31.11.				
		David A. Williamson, M.D.	hypertl	R 35.100, 35.200, iodine-131 for treatment of hyroidism and cardiac dysfunction, iodine-131 niodide for imaging and localization studies .11.				
		James Heisel, M.D.	10 CFI	R 35.100, 35.200, and 35.300.				
		Renuka M. Pat el, M.D.		R 35.100, 35.200, iodine-131 sodium iodide for g and localization studies and 31.11.				
		Bhaskar Shenai, M.D.		R 35.100, 35.200 and 35.300 (excluding iodine- r thyroid carcinoma therapy).				
		Samir Parikh, M.D.	10 CFf	R 35.100 and 35.200.				
		Mary Feng, M.D.	10 CFI	R 35.400.				
		Julie Soriano, M.D.	10 CFF	R 35.400.				
		Mohammad Asad, M.D.	10 CFI	R 35.100 and 35.200.				

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSIO				PAGE	4	of	4	PAGES	
				nse Number -00258-06					
		MATERIALS LICENSE	Doc	ket or Reference Number				<u> </u>	<u>_</u>
		SUPPLEMENTARY SHEET	030-01990						
			An	nendment No. 53					
13.	 In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance. 							ensed	
14.	The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."								
15.	5. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.								
	A. Application dated August 24, 2000 (except Quality Management Program) and July 19, 2007; and							nd	
	B. Letters dated July 27, 2006, June 1, 2007 and November 28, 2007; and								
	C. Facs	imile dated February 12, 2001.							
									-
		FO	R THE U.S.	NUCLEAR REGU		RY (сом	MISS	SION
Date	JUN	1 6 2008 By		P. Reichhold Is Licensing Branch		(al	<u>l</u>		